000838378 001__ 838378
000838378 005__ 20210129231535.0
000838378 0247_ $$2doi$$a10.1007/s00259-017-3840-z
000838378 0247_ $$2ISSN$$a0340-6997
000838378 0247_ $$2ISSN$$a1432-105X
000838378 0247_ $$2ISSN$$a1619-7070
000838378 0247_ $$2ISSN$$a1619-7089
000838378 0247_ $$2pmid$$apmid:29026951
000838378 0247_ $$2WOS$$aWOS:000415085500012
000838378 0247_ $$2altmetric$$aaltmetric:27362509
000838378 037__ $$aFZJ-2017-06990
000838378 041__ $$aEnglish
000838378 082__ $$a610
000838378 1001_ $$00000-0003-2850-9450$$aHammes, Jochen$$b0$$eCorresponding author
000838378 245__ $$aMultimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET.
000838378 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2017
000838378 3367_ $$2DRIVER$$aarticle
000838378 3367_ $$2DataCite$$aOutput Types/Journal article
000838378 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510316458_27061
000838378 3367_ $$2BibTeX$$aARTICLE
000838378 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000838378 3367_ $$00$$2EndNote$$aJournal Article
000838378 520__ $$aPurposeCerebral glucose metabolism measured with [18F]-FDG PET is a well established marker of neuronal dysfunction in neurodegeneration. The tau-protein tracer [18F]-AV-1451 PET is currently under evaluation and shows promising results. Here, we assess the feasibility of early perfusion imaging with AV-1451 as a substite for FDG PET in assessing neuronal injury.MethodsTwenty patients with suspected neurodegeneration underwent FDG and early phase AV-1451 PET imaging. Ten one-minute timeframes were acquired after application of 200 MBq AV-1451. FDG images were acquired on a different date according to clinical protocol. Early AV-1451 timeframes were coregistered to individual FDG-scans and spatially normalized. Voxel-wise intermodal correlations were calculated on within-subject level for every possible time window. The window with highest pooled correlation was considered optimal. Z-transformed deviation maps (ZMs) were created from both FDG and early AV-1451 images, comparing against FDG images of healthy controls.ResultsRegional patterns and extent of perfusion deficits were highly comparable to metabolic deficits. Best results were observed in a time window from 60 to 360 s (r = 0.86). Correlation strength ranged from r = 0.96 (subcortical gray matter) to 0.83 (frontal lobe) in regional analysis. ZMs of early AV-1451 and FDG images were highly similar.ConclusionPerfusion imaging with AV-1451 is a valid biomarker for assessment of neuronal dysfunction in neurodegenerative diseases. Radiation exposure and complexity of the diagnostic workup could be reduced significantly by routine acquisition of early AV-1451 images, sparing additional FDG PET.
000838378 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000838378 588__ $$aDataset connected to CrossRef
000838378 7001_ $$0P:(DE-HGF)0$$aLeuwer, Isabel$$b1
000838378 7001_ $$0P:(DE-Juel1)166265$$aBischof, Gérard N.$$b2
000838378 7001_ $$0P:(DE-HGF)0$$aDrzezga, Alexander$$b3
000838378 7001_ $$0P:(DE-Juel1)169110$$avan Eimeren, Thilo$$b4
000838378 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-017-3840-z$$n13$$p 2249–2256$$tEuropean journal of nuclear medicine and molecular imaging$$v44$$x1619-7089$$y2017
000838378 8564_ $$uhttps://link.springer.com/article/10.1007/s00259-017-3840-z
000838378 8564_ $$uhttps://juser.fz-juelich.de/record/838378/files/s00259-017-3840-z.pdf$$yRestricted
000838378 8564_ $$uhttps://juser.fz-juelich.de/record/838378/files/s00259-017-3840-z.gif?subformat=icon$$xicon$$yRestricted
000838378 8564_ $$uhttps://juser.fz-juelich.de/record/838378/files/s00259-017-3840-z.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000838378 8564_ $$uhttps://juser.fz-juelich.de/record/838378/files/s00259-017-3840-z.jpg?subformat=icon-180$$xicon-180$$yRestricted
000838378 8564_ $$uhttps://juser.fz-juelich.de/record/838378/files/s00259-017-3840-z.jpg?subformat=icon-640$$xicon-640$$yRestricted
000838378 8564_ $$uhttps://juser.fz-juelich.de/record/838378/files/s00259-017-3840-z.pdf?subformat=pdfa$$xpdfa$$yRestricted
000838378 909CO $$ooai:juser.fz-juelich.de:838378$$pVDB
000838378 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166265$$aForschungszentrum Jülich$$b2$$kFZJ
000838378 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)169110$$aForschungszentrum Jülich$$b4$$kFZJ
000838378 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000838378 9141_ $$y2017
000838378 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000838378 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000838378 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000838378 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000838378 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000838378 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000838378 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000838378 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000838378 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000838378 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000838378 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000838378 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000838378 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000838378 920__ $$lyes
000838378 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000838378 980__ $$ajournal
000838378 980__ $$aVDB
000838378 980__ $$aI:(DE-Juel1)INM-3-20090406
000838378 980__ $$aUNRESTRICTED